시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 아데노부속바이러스(AAV) 벡터 시장 보고서(2025년)
Adeno-Associated Viral Vectors Global Market Report 2025
상품코드 : 1702682
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

아데노부속바이러스(AAV) 벡터 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 17.6%를 나타내 60억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 치료 용도의 확대, 유전성 질환 및 신경 질환의 유병률 증가, 규제 당국의 승인과 지원, 생산 비용의 절감 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 유전자 치료의 진보, 기술 혁신, 확장 가능한 제조 공정, 공동 연구·투자, 기술 진보 등이 있습니다.

아데노부속바이러스(AAV) 벡터 시장은 유전성 질환의 유병률이 증가함에 따라 성장할 것으로 예상됩니다. 유전성 질환은 개인의 DNA 이상에서 발생하여 신체적 또는 발달 문제를 유발합니다. 진단 기술의 향상, 의식의 향상, 생식 연령의 상승, 환경의 영향, 유전적 드리프트 등의 요인이 유전성 질환의 유병률 상승에 기여하고 있습니다. 아데노부속바이러스(AAV) 벡터는 근이영양증 및 낭포성 섬유증과 같은 질환을 치료할 수 있는 표적 세포에 변형 유전자를 전달함으로써 이러한 질환에 대한 유전자 치료에 중요한 역할을 합니다. 예를 들어, 세계보건기구(WHO)가 2023년 2월에 보고한 바에 따르면, 선천성 질환에 의한 생후 28일 이내의 유아 사망수는 세계에서 연간 약 24만명, 또한 생후 1개월부터 5세까지의 소아 사망수는 17만명이었으며, 아데노부속바이러스(AAV) 벡터 시장의 원동력이 부각되었습니다.

아데노부속바이러스(AAV) 벡터 시장의 주요 기업은 경쟁력 강화를 위해 복제 캡시드 플라스미드의 기제품의 이용 가능성을 중시하고 있습니다. 예를 들어 찰스 리버 래버러토리스 인터내셔널은 2024년 1월에 기성품 복제 캡시드 플라스미드 제품군을 출시하여 AAV 기반 유전자 치료 이니셔티브를 간소화했습니다. 이를 통해 제조의 번거로움을 최대 66% 줄일 수 있습니다. 이 즉시 사용할 수 있는 플라스미드는 CMC 가이드라인을 준수하고 IND 및 임상시험 신청(CTA) 제출을 용이하게 하는 분석 증명서(COA)를 첨부한 상세한 문서화된 배치 생산이 이루어집니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염 및 경기 회복이 시장에 미치는 영향을 포함한 거시 경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses extensively used in gene therapy to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and various diseases. Their safety profile and efficient infection of both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.

The main types of AAV therapy are gene augmentation, immunotherapy, and others. Gene augmentation involves introducing a functional gene to replace or supplement a defective or missing gene in a patient's cells. This therapy can be delivered through ex vivo or in vivo methods, targeting therapeutic areas such as genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, neurological disorders, and more. The scale of operation ranges from preclinical and clinical stages to commercial applications, applied in gene therapy, cell therapy, and vaccines.

The adeno-associated viral vectors market research report is one of a series of new reports from The Business Research Company that provides adeno-associated viral vectors market statistics, including adeno-associated viral vectors industry global market size, regional shares, competitors with a adeno-associated viral vectors market share, detailed adeno-associated viral vectors market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated viral vectors industry. This adeno-associated viral vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.69 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to vaccine development, increased funding and investment, academic and industrial collaborations, expansion of clinical trials, and public awareness and advocacy.

The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expanding therapeutic applications, increasing the prevalence of genetic disorders, and neurological disorders, regulatory approvals and support, and cost reductions in production. Major trends in the forecast period include gene therapy advancements, technological innovations, scalable manufacturing processes, collaborations and investments, and technological advancements.

The adeno-associated viral vectors market is poised for growth due to the increasing prevalence of genetic disorders. Genetic disorders arise from abnormalities in an individual's DNA, leading to physical or developmental issues. Factors such as improved diagnostic techniques, greater awareness, advanced reproductive age, environmental influences, and genetic drift contribute to the rising prevalence of genetic disorders. Adeno-associated viral vectors play a crucial role in gene therapy for these disorders by delivering corrective genes into target cells, potentially treating conditions such as muscular dystrophy or cystic fibrosis. For example, the World Health Organization (WHO) reported in February 2023 that congenital diseases caused approximately 240,000 infant deaths globally within 28 days of birth annually, with an additional 170,000 deaths in children aged 1 month to 5 years, highlighting the driving force behind the adeno-associated viral vectors market.

Key players in the adeno-associated viral vectors market are emphasizing off-the-shelf availability of replication-capsid plasmids to enhance their competitiveness. Rep/Cap plasmids, widely used in gene therapy for adeno-associated virus (AAV) vector production, are readily accessible from multiple commercial suppliers catering to molecular biology research requirements. For instance, Charles River Laboratories International Inc. introduced an off-the-shelf replication-capsid plasmid range in January 2024, streamlining AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, reducing manufacturing efforts by up to 66%. These ready-to-use plasmids undergo batch production with detailed documentation, complying with CMC guidelines and accompanied by Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.

In May 2024, Merck KGaA, a Germany-based company specializing in pharmaceuticals, biotechnology, and chemical materials, acquired Mirus Bio LLC for $600 million. This acquisition allows Merck KGaA to enhance its life sciences capabilities by incorporating Mirus Bio's advanced RNA-based research and therapeutic technologies. As a result, Merck KGaA strengthens its position in the expanding genetic engineering and biotechnology markets, further advancing its commitment to developing innovative biopharmaceutical products. Mirus Bio LLC, a US-based company, specializes in adeno-associated viral (AAV) vectors and gene delivery technologies.

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

North America was the largest region in the adeno-associated viral vectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adeno-associated viral vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adeno-associated viral vectors market consists of sales of recombinant adeno-associated viral vectors (AAV), serotype-specific adeno-associated viral vectors (AAV), and custom adeno-associated viral vectors (AAV). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adeno-Associated Viral Vectors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adeno-associated viral vectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for adeno-associated viral vectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adeno-associated viral vectors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Adeno-Associated Viral Vectors Market Characteristics

3. Adeno-Associated Viral Vectors Market Trends And Strategies

4. Adeno-Associated Viral Vectors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Adeno-Associated Viral Vectors Growth Analysis And Strategic Analysis Framework

6. Adeno-Associated Viral Vectors Market Segmentation

7. Adeno-Associated Viral Vectors Market Regional And Country Analysis

8. Asia-Pacific Adeno-Associated Viral Vectors Market

9. China Adeno-Associated Viral Vectors Market

10. India Adeno-Associated Viral Vectors Market

11. Japan Adeno-Associated Viral Vectors Market

12. Australia Adeno-Associated Viral Vectors Market

13. Indonesia Adeno-Associated Viral Vectors Market

14. South Korea Adeno-Associated Viral Vectors Market

15. Western Europe Adeno-Associated Viral Vectors Market

16. UK Adeno-Associated Viral Vectors Market

17. Germany Adeno-Associated Viral Vectors Market

18. France Adeno-Associated Viral Vectors Market

19. Italy Adeno-Associated Viral Vectors Market

20. Spain Adeno-Associated Viral Vectors Market

21. Eastern Europe Adeno-Associated Viral Vectors Market

22. Russia Adeno-Associated Viral Vectors Market

23. North America Adeno-Associated Viral Vectors Market

24. USA Adeno-Associated Viral Vectors Market

25. Canada Adeno-Associated Viral Vectors Market

26. South America Adeno-Associated Viral Vectors Market

27. Brazil Adeno-Associated Viral Vectors Market

28. Middle East Adeno-Associated Viral Vectors Market

29. Africa Adeno-Associated Viral Vectors Market

30. Adeno-Associated Viral Vectors Market Competitive Landscape And Company Profiles

31. Adeno-Associated Viral Vectors Market Other Major And Innovative Companies

32. Global Adeno-Associated Viral Vectors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adeno-Associated Viral Vectors Market

34. Recent Developments In The Adeno-Associated Viral Vectors Market

35. Adeno-Associated Viral Vectors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기